Crossject SA

Paris Stock Exchange ALCJ.PA

Crossject SA Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD 3.71 M

Crossject SA Net Cash Used Provided By Financing Activities is USD 3.71 M for the year ending December 31, 2023, a -64.06% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

Crossject SA Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD 10.31 M, a -37.61% change year over year.
Crossject SA Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD 16.53 M, a 13.44% change year over year.
Crossject SA Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD 14.57 M, a -0.09% change year over year.
Crossject SA Net Cash Used Provided By Financing Activities for the year ending December 31, 2019 was USD 14.59 M, a -4.19% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

Paris Stock Exchange: ALCJ.PA

Crossject SA

CEO	Mr. Patrick Alexandre
IPO Date	Feb. 20, 2014
Location	France
Headquarters	6 Rue Pauline Kergomard
Employees	105
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Drugstores & Retail Pharmacies

Description

Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.

Key trends

Past 5 years